How to access Vyvgart from the UAE — the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
A UAE patient living with generalised myasthenia gravis (gMG) may receive a prescription for Vyvgart (efgartigimod alfa-fcab) from their treating neurologist or neuromuscular specialist. Vyvgart is FDA-approved for gMG in adult patients who are anti-acetylcholine receptor (AChR) antibody positive, and it is manufactured by argenx. It is the first neonatal Fc receptor (FcRn) antagonist approved for gMG — a mechanism that reduces pathogenic IgG autoantibodies without the broad immunosuppression of corticosteroids, steroid-sparing agents, or B-cell depleters. In the UAE, Vyvgart may not yet be broadly registered, which is why your neurologist may be navigating a named-patient import pathway with you.
This guide explains the legal pathway, what your physician needs to provide, typical timelines, and where Reserve Meds fits in.
The clinical situation
Vyvgart (IV formulation) is administered as a one-hour IV infusion of 10 mg/kg once weekly for four weeks, with additional treatment cycles initiated based on clinical evaluation (typically every several weeks to months depending on response). A subcutaneous formulation (Vyvgart Hytrulo, efgartigimod alfa + hyaluronidase) is also available with a shorter administration time. Eligibility typically requires confirmed AChR-antibody seropositivity, an MGFA clinical classification, and a pre-treatment screening bundle (vaccinations, infection screen). Your treating neurologist confirms diagnosis, screening status, and the infusion plan per FDA labeling.
Is Vyvgart legally importable into the UAE?
Yes — through the UAE Ministry of Health and Prevention (MoHAP) named-patient framework, with parallel authority through DoH Abu Dhabi and DHA Dubai depending on the prescribing facility. The pathway allows a UAE-licensed physician to import a medicine not locally registered when: (a) the medicine is approved by a recognised reference authority (FDA qualifies), (b) no locally available alternative is clinically equivalent for the patient, (c) the physician takes clinical responsibility, and (d) chain of custody is documented.
For Vyvgart specifically, the application integrates the infusion-facility plan for the IV formulation; the subcutaneous formulation can be administered in a clinic or, per your physician's judgement, at home once technique is established.
How the pathway works, step by step
- Consultation with your treating neurologist. AChR antibody confirmation, gMG clinical diagnosis, MGFA classification, and pre-treatment screening.
- Formulation selection. IV (Vyvgart) versus subcutaneous (Vyvgart Hytrulo) — a clinical decision based on infusion logistics and patient preference.
- Infusion facility identification (if IV). The administering facility must be equipped to manage infusion reactions.
- MoHAP / DoH / DHA named-patient application. Your physician files the application.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner.
- Cold-chain shipment. Vyvgart ships at 2–8°C with continuous temperature monitoring.
- Arrival and cycle administration. The licensed facility administers the four-weekly cycle; additional cycles are scheduled per clinical response.
What documentation your physician needs
Your physician will typically need to provide:
- Clinical rationale letter confirming gMG diagnosis, AChR antibody positivity, MGFA class, and prior therapy history
- Verification of UAE medical licence
- Identification of the administering infusion facility (for IV formulation)
- Patient identifier
- Pre-treatment screening results and vaccination record
- Planned cycle schedule
Reserve Meds provides a physician documentation kit that bundles the templates MoHAP reviewers expect to see for FcRn-antagonist therapy.
Costs and timing
Vyvgart's US cash-pay reference price sits in a broad indicative range — the annualised treatment cost varies with dosing frequency but falls in the USD 400,000–600,000 range in US list pricing, depending on number of cycles per year. International cold-chain logistics, MoHAP documentation, and concierge coordination add incremental cost; Reserve Meds issues a full transparent quote at the start of intake. These ranges are indicative, not guaranteed.
Indicative timing — not guaranteed — for the first infusion after cohort intake opens is approximately 14–28 days from the moment a complete application is submitted.
Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.
Reserve Meds's role
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Vyvgart specifically, we provide:
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and for MoHAP/DoH/DHA review.
- Logistics. Cold-chain, temperature-monitored shipment.
- Concierge case lead. A named point of contact.
What we do not do: We are not the prescriber. We do not practise medicine. We are not the dispensing pharmacy. All clinical decisions remain with your treating neurologist.
Frequently asked
Is this legal in the UAE? Yes, when executed through the MoHAP named-patient framework with appropriate documentation.
How does Vyvgart compare with Rystiggo or Zilbrysq for gMG? Vyvgart and Rystiggo are both FcRn antagonists (Rystiggo is fully subcutaneous); Zilbrysq is a complement C5 inhibitor (daily subcutaneous self-injection, with meningococcal vaccination gating). The choice depends on antibody status, dosing preference, infusion access, and infection-risk profile.
What about vaccinations? Vyvgart reduces IgG levels broadly, which can reduce vaccine response. Vaccinations should be up-to-date before starting, and your neurologist coordinates any new vaccinations around the cycle schedule.
Will private insurance cover this? Cash-pay is the default. Some UAE private insurers reimburse gMG biologic therapy on escalated review; we supply documentation but do not process insurance claims directly.
Next step — join the first-cohort waitlist
Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Vyvgart coordination in the UAE.
Add me to the Vyvgart waitlist> Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.